User:Mr. Ibrahem/Vorinostat

Vorinostat, sold under the brand name Zolinza, is a medication used for cutaneous T cell lymphoma (CTCL). Specifically it is used when the disease persists, gets worse, or comes back during or after two other treatments. It is taken by mouth.

Common side effects include diarrhea, tiredness, change in taste, low platelets, hair loss, cough, and fever. Other severe side effects may include blood clots and high blood sugar. Use during pregnancy may harm the baby. It is a histone deacetylase inhibitors (HDI).

Vorinostat was approved for medical use in the United States in 2006. While it was given orphan medication status in Europe in 2004, in 2009 the application for approval was withdrawn. In the United States it costs about 14,600 USD per month as of 2021.